PR Newswire
SAN FRANCISCO , Feb. 23, 2021 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that members of its management team will participate in the following virtual investor conferences in March:
- Cowen 41st Annual Healthcare Conference on Tuesday, March 2, 2021
- 2021 H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021
A live webcast, if recorded, of Company presentations and Q&A will be available through the investor relations section of the Company's website at www.akerotx.com . Following the live webcasts, archived replays will be available on the Company's website.
About Akero Therapeutics
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead program, EFX, an engineered Fc-FGF21 fusion protein, is currently being evaluated in Phase 2 clinical trials as a potential treatment for NASH. Akero is headquartered in South San Francisco . Visit us at www.akerotx.com for more information.
Investor Contact:
Christina Tartaglia
212.362.1200
IR@akerotx.com
Media Contact:
Jennifer Weismann
612-716-0556
media@akerotx.com
SOURCE Akero Therapeutics